Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A case study of myopericarditis due to immune checkpoint inhibitor therapy: Proposed surveillance and management

A case study of myopericarditis due to immune checkpoint inhibitor therapy: Proposed surveillance... ABSTRACTImmune checkpoint inhibitor (ICI) therapy is a treatment modality used in many types of cancer. Immune-related adverse events are relatively common. Cardiovascular adverse events are uncommon, but carry a high mortality rate of 25–50%. They require cessation of therapy. There is currently no universal screening before initiation of ICI therapy to identify patients with cardiovascular risk. There is also no ongoing screening to identify myocarditis and treatment is driven by symptoms. This article provides a case study of a patient who developed myopericarditis and the patient's clinical course. Furthermore, it proposes surveillance for patients before and during ICI therapy to swiftly identify potential cases of myocarditis. There is currently no universal baseline screening for cardiovascular risk in patients planned for ICI therapy. A proposed baseline cardiac evaluation, as well as scheduled surveillance therapy, is outlined in this article. With further education and training, immune-related cardiac adverse events may be more promptly detected, leading to better patient outcomes. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the American Association of Nurse Practitioners Wolters Kluwer Health

A case study of myopericarditis due to immune checkpoint inhibitor therapy: Proposed surveillance and management

Loading next page...
 
/lp/wolters-kluwer-health/a-case-study-of-myopericarditis-due-to-immune-checkpoint-inhibitor-CQ9XMwi05v

References (11)

Publisher
Wolters Kluwer Health
Copyright
© 2023 American Association of Nurse Practitioners
ISSN
2327-6886
eISSN
2327-6924
DOI
10.1097/jxx.0000000000000860
Publisher site
See Article on Publisher Site

Abstract

ABSTRACTImmune checkpoint inhibitor (ICI) therapy is a treatment modality used in many types of cancer. Immune-related adverse events are relatively common. Cardiovascular adverse events are uncommon, but carry a high mortality rate of 25–50%. They require cessation of therapy. There is currently no universal screening before initiation of ICI therapy to identify patients with cardiovascular risk. There is also no ongoing screening to identify myocarditis and treatment is driven by symptoms. This article provides a case study of a patient who developed myopericarditis and the patient's clinical course. Furthermore, it proposes surveillance for patients before and during ICI therapy to swiftly identify potential cases of myocarditis. There is currently no universal baseline screening for cardiovascular risk in patients planned for ICI therapy. A proposed baseline cardiac evaluation, as well as scheduled surveillance therapy, is outlined in this article. With further education and training, immune-related cardiac adverse events may be more promptly detected, leading to better patient outcomes.

Journal

Journal of the American Association of Nurse PractitionersWolters Kluwer Health

Published: Mar 30, 2023

There are no references for this article.